Abstract
Introduction; Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a sporadic but underdiagnosed pulmonary disorder at the benign end of the neuroendocrine cell proliferation spectrum of preinvasive lesions of the lungs. This disease is characterized by hyperplasia of bronchiolar and bronchial pulmonary neuroendocrine cells. DIPNECH can be primary or reactive.
In the WHO - IASLP classification of lung tumors (1999, 2004, 2005, 2015), DIPNECH is considered a preneoplastic lesion in the spectrum of pulmonary tumors. According to the WHO classification, the definition of DIPNECH is purely histological.
The DIPNECH was initially described in 1992 by Aguayo et al., who reported six non-smoking patients with cough, exertional dyspnea, wheezing, less frequent hemoptysis, and a mixed obstructive/restrictive defect on pulmonary function tests. This disease has a predilection for non-smoking middle-aged women (female to male ratio is approximately 10:1)
In this article, we present a 62-year-old, non-smoker woman presented with respiratory symptoms ascribable to DIPNECH. After surgery, the morphological study of lung specimens confirmed the DIPNECH, multiple tumors, one peripheral carcinoid, and obliterative bronchiolitis in the right middle pulmonary lobe.
Conclusions: DIPNECH remains a rare pulmonary condition and is considered a preneoplastic lesion in the spectrum of pulmonary tumors. According to the WHO classification, the definition of DIPNECH is purely histological. While most patients experience a relatively uneventful clinical course, this condition may be associated with tumors, carcinoid tumors, and airway obstruction (Aguayo-Miller disease).
References
2. Travis WD, et al. (2004). WHO classification of tumors: Pathology & Genetics: Tumours of the lung, pleura, thymus, and heart. Lyon, France: IARC Press; pp. 19 – 21
3. Travis WD, Brambilla E, Burke AP, et al. (2015). WHO classification of lung, pleura, thymus, and heart tumors. Lyon: IARC Press; pp. 78–79.
4. Daniel R. Almquist, Vinicius Ernani, Mohamed Bassam Sonbol. (2021) Diffuse idiopathic pulmonary neuroendocrine cell Hyperplasia: DIPNECH. Curr. Opin. Pulm. Med. Jul 1; 27, 255
5. Jin, Linfang ; Wang, Zhiqiang ; Qi, Xiaowei. (2018). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.Case series and a review of the literature. Medicine, Vol. 97, p 13806
6. Giulio Rossi, Alberto Cavazza et. Al. (2016). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia Syndrome. European Respiratory Journal, 47. pp. 1829 – 1841
7. Evangelos Koliakos. (2017). Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia. A Case Report and Review of the Literature. American Journal Case Report, 18: pp. 975 – 979
8. Benson RE, Rosado-de-Christenson ML, Martínez-Jiménez S, et al. (2013). The spectrum of pulmonary neuroendocrine proliferations and neoplasms. Radiographics, 33: 1631 – 1649.
9. Cansız Ersöz C, Cangır AK, Dizbay Sak S. (2016). Diffuse neuroendocrine cell hyperplasia: Report of two cases—case Report Pathology, 34, p. 19725.
10. Nassar AA, Jaroszewski DE, Helmers RA, et al. (2011). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: A systematic overview. American Journal Respiratory Crit Care Med, 184: pp. 8 – 12
11. Marchevsky AM, Wirtschafter E, Walts AE. (2015). The spectrum of changes in adults with multifocal pulmonary neuroendocrine proliferations: What are the minimum pathologic criteria for diagnosing DIPNECH? Human Pathology, 46: pp. 176 – 181.
12. Wirtschafter E, Walts AE, Liu ST, et al. (2015). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung (DIPNECH): Current best evidence. Lung, 193: pp. 659 – 667.
13. Davies SJ, Gosney JR, Hansell DM, et al. (2007). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: An under-recognized spectrum of disease. Thorax, 62: pp. Pp. 248 – 252.
14. Carr LL, Chung JH, Achcar RD, et al. (2015). The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest, 147: pp. 415 – 22.
15. Schnabel PA, Junkel K. (2015). Pulmonary neuroendocrine tumors in the new 2015 WHO classification. Start of breaking new grounds? Pathology, 36: pp. 383 – 392
16. Luis Cabezón - Gutiérrez, Parham Khosravi-Shahi , Magda Palka-Kotlowska , Sara Custodio Cabello, Maria García-Martos. (2019). Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review of the Literature and a Single-center Experience. Cureus: pp. 35 - 45
17. Gorshtein A, Gross J, Barak D, Strenov Y, Refaeli Y, Shimon I, Grozinsky‐Glasberg S. (2012). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity. Cancer, 118: pp. 612 – 619
18. Chauhan A, Ramirez RA: 2015, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and the role of somatostatin analogs: a case series. Lung, 193: 653 – 657
19. Lutfi Alia. (2019). Diffuse hyperplasia of pulmonary neuroendocrine cells: "Pathological bases of diseases." Tirana: "Streha" Publishing House, vol I, pp. 259 – 263
20. Godwin Ofikwu. (2015). A rare Case of Diffuse Idiopathic Pulmonary Neuroendocrine cell Hyperplasia. A case report in Surgery. 31, pp. 5 – 8.
21. Joshua Yap. (2022). Diffuse idiopathic pulmonary neuroendocrine cell Hyperplasia: DIPNECH Radiopaedia. Aug 6, pp. 121 – 125
22. Eva García-Fontán, Montserrat Blanco Ramos, Jose S. Garcia, Rommel Garrasco, Miguel Àngel Cañizares, Ana Gonzales Piñiero. (2019). Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Report of two cases. Med. Clin. (Barc), Feb 1; 152 (3): 1044 – 106
23. Chu Xiao at al. (2022) Neuroendocrine transformation from EGFR/ALK-wild type, or TKI naïve non-small cell lung cancer. Lung Cancer. May 16, p. 22 -30
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.